3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
8
Breast
7
Gastrointestinal
4
CNS
2
Tumor-Agnostic
1
Other solid neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Brain Neoplasms
2
Meningeal Neoplasms
1
Breast Neoplasms
1
Interventions
Temozolomide
166
Magnetic Resonance Spectroscopy
131
Radiotherapy
97
Specimen Handling
81
Radiosurgery
61
Cyclophosphamide
56
pembrolizumab
52
Bevacizumab
52
Radiation
48
Nivolumab
48
Carboplatin
36
Biopsy
33
Irinotecan
29
Etoposide
25
Vincristine
24
Lomustine
24
Topotecan
23
Ipilimumab
23
Blood Specimen Collection
23
Cisplatin
22
dinutuximab
21
fludarabine
19
Surgical Procedures, Operative
19
Radiotherapy, Intensity-Modulated
19
X-Rays
18
abemaciclib
16
Mental Status and Dementia Tests
16
Granulocyte-Macrophage Colony-Stimulating Factor
16
Pemetrexed
15
atezolizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
patritumab deruxtecan
×
CNS
×
1 year
×
Clear all
NCT05865990
2026-05-04
TUXEDO-3
MedSIR
Phase 2
Completed
63 enrolled
NCT05620914
2025-06-15
PARAMETer
Duke University
Phase 2
Withdrawn